Latest news
Watch: TVG CEO Jeremy Salt on BRSV vaccine success and next steps
The Vaccine Group has reported exceptional results for two vaccines to tackle a major cause of damaging bovine respiratory diseases, bovine respiratory syncytial virus.
Read moreOutstanding success for TVG in trials of vaccines to combat major livestock disease
The Vaccine Group has enjoyed outstanding success in trials of two vaccines to combat bovine respiratory syncytial virus (BRSV). The disease harms both beef and dairy cattle, and is estimated to cost farmers globally £5.6 billion a year.
Read moreWatch: Amprologix CSO Mat Upton on the first in a new class of antibiotics
Amprologix Chief Scientific Officer Mat Upton discusses the company’s recent fund raising raising, plans for a Series A round and the future of its novel antibiotics to tackle resistant diseases.
Read moreOur portfolio
Our portfolio companies are involved in developing a wide range of technologies based on cutting-edge intellectual property to meet the needs and demands of the world.
See all companiesDekiln
Dekiln, formerly known as DeakinBio, has developed BioSintering®, a technology combining waste materials such as gypsum powder with bio-based active ingredients to produce a revolutionary, low-carbon alternative to traditional ceramic tiles.
Learn moreShare price
Share Price InformationLatest downloads
Half Year Results 2024/25
